RxDoctor Payments Data

Thomas Brush, MD

Urology · Lincoln, NENPI 1669889200

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (38.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Angiodynamics, Inc. at 43.0% of the total. 2025 is the largest year on record at $6,907, more than ten times the $673 reported in 2019.

$14,644in general payments, 2019–2025

Across 252 payments — averaging $58.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$6K
  • Axonics, Inc.$3K
  • Teleflex LLC$1K
  • Astellas Pharma US Inc$527
  • Johnson & Johnson$446
  • Coloplast$344
  • plus $3K from 45 others

What the payments were for

  • Travel & lodging$3,16322%
  • Food & beverage$5,36437%
  • Education$4783%
  • Other$5,63939%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,644 in reported general payments places this provider in the 85th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Medicare billing

Part B allowed, 2024
$318,907
Medicare patients
593
Services billed
6,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide57$759,930
MyrbetriqMirabegron108$68,615
GemtesaVibegron53$32,009
OrgovyxRelugolix12$28,463
RenacidinCitric Ac/Gluconolact/Mag Carb14$1,525
Tamsulosin Hcl107$1,372
Methenamine Hippurate13$1,186
Oxybutynin Chloride ErOxybutynin Chloride44$526
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$373
Finasteride23$234
Oxybutynin Chloride13$181
Ciprofloxacin Hcl34$171
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim40$144
Tramadol Hcl23$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$527$828,546165 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$201$60,47265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 urology providers in Nebraska.

Other urology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →